Sanne has more than 20 years of combined academic and biotech industry experience. Before the acquisition by AstraZeneca, Sanne was VP of Corporate Strategy at Neogene Therapeutics, a company developing novel TCR-T Cell Therapies. Prior to that, she worked as the COO of Scenic Biotech and as an independent consultant for early stage biotech companies. She started her industry career at Aglaia Biomedical Ventures, investing in early stage biotech companies in oncology, where she ultimately became partner.

More recently, Sanne is part of the Cell Therapy Discovery leadership team at AstraZeneca, responsible for managing the early stage Cell Therapy portfolio of programs as well as ensuring a smooth and efficient global Cell Therapy discovery operations.

Dr. Weijzen earned her Master’s degree in Biomedical Sciences from the University of Leiden and did her PhD research at Cardinal Bernadin Cancer Center, Loyola University Chicago in Tumor Immunology in the lab of Prof. Martin Kast. She completed her post-doctoral fellowship in molecular cancer cell signaling at the University of Utrecht.